Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Primycin→

Primycin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
113443-41-7
Molecular formula
Not available
Molecular weight
Not available
Drug class
Polyene macrolide antibiotictopical local anti-infective agent
Mechanism of action
A polyene antibiotic complex that interacts with sterols in microbial membranes, altering membrane integrity and permeability. Activity and spectrum depend on the specific primycin preparation and formulation.
Indications / reported uses
  • Topical treatment of selected superficial bacterial and fungal skin infections with primycin-containing preparations where authorised; this is not a systemic antibiotic indication.

Sources: https://pubchem.ncbi.nlm.nih.gov/#query=primycin · https://www.ncbi.nlm.nih.gov/mesh/?term=primycin · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Primycin Environmental Risk Assessment (ERA) (the Primycin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.